This study is testing a new device called a "nanosensor" to measure oxygen levels in muscle. This nanosensor is very small (1.8 mm wide x 6 mm long x 0.3 mm deep) and has not been tested in humans or approved by the FDA. The goal is to see if it can accurately measure mitochondrial function (how your cells produce energy) in people with mitochondrial myopathies (a type of mitochondrial disease) and healthy volunteers. Researchers hope this nanosensor can help determine how severe mitochondrial disease is, how it progresses, and how well new treatments work. You may be eligible if you are between 18 and 65 years old, can walk independently, and can perform bicycle exercise. For those with mitochondrial myopathy, additional criteria apply. The study aims to enroll 96 participants.

Study design

This is an interventional study testing a device. It will involve both healthy volunteers and individuals with mitochondrial myopathy.

What's involved

You would have a nanosensor placed in your forearm under local anesthesia. Researchers will measure muscle oxygen levels during handgrip exercises and after a cardiopulmonary exercise test (CPET). They will also assess your pain.

Compensation

Not stated in the trial record.

Follow-up

Nanosensor-muscle oxygen levels will be measured up to 4 hours or up to 40 days after the screening visit for handgrip exercises, and up to 1 hour after CPET.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.